Article
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Journal for immunotherapy of cancer - 1 Jul 2023
Rozeman Elisa A, Versluis Judith M, Sikorska Karolina, Hoefsmit Esmée P, Dimitriadis Petros, Rao Disha, Lacroix Ruben, Grijpink-Ongering Lindsay G, Lopez-Yurda Marta, Heeres Birthe C, van de Wiel Bart A, Flohil Claudie, Sari Aysegul, Heijmink Stijn W T P J, van den Broek Daan, Broeks Annegien, de Groot Jan Willem B, Vollebergh Marieke A, Wilgenhof Sofie, van Thienen Johannes V, Haanen John B A G, Blank Christian U
Abstract excerpt
BACKGROUND: Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatment-related adverse events (TRAE) in patients with BRAFV600-mutated melanoma. Short-term MAPKi induces T-cell infiltration in patients and is synergistic with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.